Key facts
- It has raised $16.6M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Innovate UK, MassChallenge, Techstart Ventures, Clarendon Fund Managers, Invest Northern Ireland — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Re-Vana
- ·The full record, as it builds
Funding rounds
No funding rounds for Re-Vana are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Re-Vana
Developer of a biodegradable drug delivery platform designed to address ophthalmic conditions. The company's platform uses pre-formed, photo-crosslinked biodegradable implants to facilitate sustained intraocular release of active pharmaceutical ingredients and a patented system that involves the injection of a gel into the eye using a narrow gauge, enabling healthcare providers and pharmaceutical companies to save costs and patients to receive reduced pain, side effects, and treatment frequency.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2015
- Employees
- 21
- Website
- revanatx.com/
- Ownership
- Privately Held (backing)
Re-Vana doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Re-Vana shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Re-Vana in its N-PORT filings yet. We sweep new filings monthly.